(A Top Pick Dec 07/17, Down 10%) He likes aerospace and defense. He would not buy it today because the valuation is high and it is cyclical. Trump this week flagged how much they are spending on defense.

(A Top Pick Dec 07/17, Down 22%) Materials were down broadly. There is unquestionable value to be realized. Ultimately the input costs won and it has not performed as well as expected.

(A Top Pick Dec 07/17, Down 5%) He got out months ago. They technically stopped out of his process.

Memory chips. Margins used to be fantastic. The semis and memory manufacturers are a great long term investment. He is on board. They are doing a good job. He would not buy it today because it does not check the technical box. You are in a negative earnings revision cycle.

A great company. Generics are fantastic. There are internal issues. A lot of people are getting lured here by single digit earnings growth. The fundamental picture is not strong here. He would take the loss. He would look at an ETF if you want to stay invested in Pharma. (Analysts’ price target is $23.00)

He likes it. It has a wild valuation, though. It has been slapped around rather hard. This is high growth, higher reward, higher risk. Fin tech he likes. One of the biggest risks is the copycat risk. It is a disruptor. It has first-mover advantage. He would not buy it now, but likes Visa and MasterCard.

There is some real growth and application but the company has struggled to be identified. You would hope to see a little more from them over 10 years. You realize a bunch of value and then it gets stuck in the soup again. There are simpler stories out there. It is trading rich for a story with volatile earnings.